Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.This news has energized investors as the broader market is experiencing gains, with the Nasdaq up 0.51%.Among the first six evaluable patients treated with lifileucel monotherapy, the trial showed a 50% confirmed objective response rate (ORR).The trial, conducted by Memorial Sloan Kettering Cancer Center, f ...